A spinout of the University of Southern California, Pivotal Biosciences, is benefiting from the approval of a $3.5M drug development project that was just approved by the National Cancer Institute, for developing a treatment for metastatic melanoma and metastatic renal cell carcinoma. According to USC, Alan Epstein, M.D., Ph.D., a professor in the firm's Department of Pathology at the USC Keck School of Medicine of USC, just received the $3.5M award from the National Cancer Institute. The technology being developed by Epstein has been licensed to privately held Pivotal Biosciences, which is headed by Dimitri Villard.
Top NewsThursday, July 9, 2009
USC Spinout Gains From $3.5M Award